Effects of Intraperitoneal Chemotherapy on Uterine Blood Flow in Patients with Postmenopausal Cervical Carcinoma Evaluated by Color Doppler Ultrasonography

  • Jianguo Huang, Ultrasound Department of Hubei Cancer Hospital, China
  • Li Zha, Ultrasound Department of Hubei Cancer Hospital, China
  • Shu-e Zeng, Ultrasound Department of Hubei Cancer Hospital, China
  • Objective: To evaluate cervical cancer hemodynamic changes after intraperitoneal chemotherapy, and its clinical significance using color Doppler ultrasonography.
    Methods: Cis-platinum diaminodichloride (PDD) 100-120mg/m 2 was injected into the patients with cervical squamous cell carcinoma, PDD 80-100mg/m2and 5-FU 1.5g per time were injected into the patients with cervical adenocacinoma. 1000-1500ml physiological saline in which the medicine was dissolved was once injected into the abdominal cavity by intraperitoneal puncturing. The course of treatment were 1-4 times. Color Doppler ultrasonography was performed in 58 patients with postmenopausal cervical carcinoma treated with intraperitoneal chemotherapy.
    Results: Chemotherapy caused the peak-systonic blood flow velocity of uterine artery decreased. The blood signals inside and around the tumor decreased. Uterine artery was not detected by color Doppler ultrasound in 50%(29/58) patients, and the echo from cervical blood vessel was normal in 81%(47/58) patients. After chemotherapy, the uterine artery RI values detected >0.6 was 79% (23/29). The uterine artery peak-systonic blood flow velocity was ≤ 40cm/s in 93% (27/29) patients. All the above parameters, compared with the parameters before chemotherapy, were markedly different (P<0.01). The decrease of intratumoral vascularity and reduction of blood flow velocity of uterine artery with increase RI during the chemotherapy were associated with better results. However, persistence of excessive vascularity at the end of chemotherapy needed further treatment.
    Conclusions: These results suggested that color Doppler ultrasonography might be useful in the early assessment of vascular therapeutic response to chemotherapy. Modifying the treatment schedules according to early therapeutic response may help achieve better outcome.